Marizyme, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRZM research report →
About the company
Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics.
- CEO
- David L. Barthel
- IPO
- 2010
- Employees
- 13
- HQ
- Jupiter, FL, US
Price Chart
- Market Cap
- $39.54K
- P/E
- -0.00
- P/S
- 0.06
- P/B
- -0.00
- EV/EBITDA
- -0.37
- Div Yield
- 0.00%
- Gross Margin
- 36.99%
- Op Margin
- -5278.10%
- Net Margin
- -10767.77%
- ROE
- -1089.84%
- ROIC
- -175.14%
- Revenue
- $645.81K · 176.60%
- Net Income
- $-69,539,336 · -82.20%
- EPS
- $-1.53 · -62.77%
- Op Income
- $-34,086,516
- FCF YoY
- 56.83%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.97
- Avg Volume
- 1.75K
Get TickerSpark's AI analysis on MRZM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 21, 23 | Braeden Lichti | other | 3,815,294 |
| Dec 21, 23 | Braeden Lichti | other | 2 |
| Jun 29, 23 | Lichti Braeden | sell | 106,327 |
| Jul 7, 23 | Lichti Braeden | sell | 97,000 |
| Aug 29, 23 | Lichti Braeden | sell | 105,000 |
| Jun 29, 23 | Lichti Braeden | buy | 106,327 |
| Jul 7, 23 | Lichti Braeden | buy | 97,000 |
| Aug 29, 23 | Lichti Braeden | buy | 105,000 |
| Apr 14, 23 | Dhaduk Vithalbhai D | other | 1,063,938 |
| Apr 14, 23 | Dhaduk Vithalbhai D | other | 1,063,938 |
Our MRZM coverage
Recent articles, reports, and earnings notes.
No research on MRZM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MRZM report →Similar companies
Peers in the same neighborhood.